Co-founded by Aleksander S. Popel, PhD and Jordan J. Green, PhD at Johns Hopkins University, AsclepiX is building a company and culture focused on transforming the treatment of disease in ophthalmology and oncology.
To date, anti-VEGF treatment has been the gold standard for treating retinal disease; however, many patients do not have a complete and lasting response with currently approved therapies. In patients who do respond, the short duration of action of these treatments requires the additional burden of recurring and frequent intravitreal injections. There is a need for more efficacious medicines that require fewer injections and reduces the treatment burden for patients.
Our mission is to go well beyond the capabilities of today’s therapies. We do this by translating brilliant scientific discovery into tomorrow’s transformative medicines that have the potential to bring better and dramatically lasting health to people throughout the world.
In ophthalmology, we are initially focused on three of the leading causes of blindness in adults: diabetic macular edema (DME), neovascular (wet) age-related macular degeneration (wet AMD), and macular edema following retinal vein occlusion (RVO). In addition to a novel mechanism of action in the treatment of these diseases, we seek to achieve superior efficacy with significantly fewer injections than approved therapies, substantially reducing the treatment burden for patients.
In oncology, we are developing treatments to activate anti-tumor immunity, inhibit metastasis, and enhance efficacy in combination with immunotherapy and chemotherapy. Early results in animal models show inhibition of tumor growth and improved survival in triple-negative breast cancer and hepatocellular carcinoma and inhibition of metastasis in triple-negative breast cancer.